Relay Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Relay Therapeutics (NASDAQ:RLAY) reported Q4 earnings, beating estimates with an EPS of $-0.67 against an expected $-0.73, an 8.22% beat. However, revenue was down $253 thousand from the same period last year. Following last quarter's earnings beat, RLAY's share price increased by 1.62% the next day.
February 22, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relay Therapeutics beat Q4 earnings estimates but reported a decrease in revenue compared to last year. Last quarter's earnings beat resulted in a 1.62% increase in stock price the following day.
The positive earnings beat suggests a potential short-term positive impact on RLAY's stock price, similar to the last quarter's performance post-earnings announcement. However, the decrease in revenue could temper some of the positive sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100